Advanced searches left 3/3

Influenza Vaccine - Europe PMC

Summarized by Plex Scholar
Last Updated: 11 September 2022

* If you want to update the article please login/register

Generation of an avian influenza DIVA vaccine with a H3-peptide replacement located at HA2 against both highly and low pathogenic H7N9 virus.

Here's update on the newly spreadable H7N9 avian influenza virus, a DIVA vaccine strain, named rGD4 HALo-MH3 -TX, based on a substituted 12 peptide of H3 virus found in HA2. The rGD4 HALo-MH3 -TX strain had similar reproductive capabilities with rGD4 and low pathogenicity in chickens, providing a high yield and safety. rGD4 HALo-mH3-TX In immune chickens, a similar antibody level as rGD4 was generated with rGD4 that resulted in a similar immune response and 90% protected against a high pathogenic virus challenge. Moreover, serological DIVA characteristics were analyzed by a newly established competitive inhibition ELISA based on a 3G10 monoclonal antibody, and the results revealed a strong reactivity with H7 subtype strains vaccinated with H7 subtype strains but not rGD4 HALo-MH3 -TX. rGD4 HALo-mH3 -TX is a promising DIVA vaccine candidate against both high and low pathogenic H7N9 subtype AIV.

Source link: https://europepmc.org/article/MED/35286234


Associated virus-bacterial vaccine based on seasonal LAIV and S. pneumoniae chimeric peptide provide protection against post-influenza pneumococcal infection in mouse model.

We tested an associated virus-bacterial vaccine based on seasonal live influenza vaccines and a S. pneumoniae chimeric protein comprising flagellin in a mouse model, as well as a flagellin. In comparison to each vaccine preparation alone, the immunogenicity of LAIV and PSPF in the associated vaccine mixture was occasionally reduced. During the development of associated virus-bacterial vaccines intended for the prevention of severe post-influenza bacterial infections, the investigation of influenza viruses' interactions with bacterial peptides is crucial.

Source link: https://europepmc.org/article/MED/35266442


A qualitative analysis of an online teaching intervention to encourage favorable attitudes toward influenza vaccine among community college students.

During the Fall 2020 semester, the aim was to raise the risk of a "twin-demic" outbreak of influenza and COVID-19 among community college students. Participants: A random sample of 185 students enrolled in an entry-level health program. Conclusions: An online teaching intervention may be highly effective in changing attitudes, referencing scientific norms, and increasing knowledge.

Source link: https://europepmc.org/article/MED/36084248


Acceptance of Seasonal Influenza Vaccine Following COVID-19 Vaccination: A Survey among Israel Defense Forces Soldiers.

The contribution of COVID-19 vaccine rollouts to real-world influenza vaccination uptake remains uncertain. This cross-sectional, research-based study among Israel Defense Forces soldiers aimed to investigate the effects of the COVID-19 pandemic and specifically, the first COVID-19 vaccine uptake on the intention to vaccinate for influenza during 2021-2022. 52. 3 percent said they are healthy and have no desire for the vaccine, and 36. 2% reported that they received too many vaccines in the last year. Because of the prevalence of COVID-19 vaccine administration in the post-COVID-19 vaccine era, influenza vaccination rates in the post-COVID-19 vaccine period may be reduced due to a suspected vaccine saturation" phenomenon, according to the results of this report. Repeated doses of COVID-19 vaccine administration should be addressed in future studies, as well as campaigns related to raising influenza vaccination coverage.

Source link: https://europepmc.org/article/MED/36073723


Post-marketing Surveillance of a Quadrivalent Influenza Vaccine (Vaxigrip Tetra) in South Korea.

Introduction In 2017, a quadrivalent inactivated split-virion influenza vaccine was licensed in South Korea for active vaccination against influenza A and influenza B viruses in children aged 3 years and older, which was then extended to people aged 6 months or older in 2018. Methods This was an open, multicenter, observational, active safety surveillance study carried out in South Korea between 20 June 2017 and 19 June 2021 at ten study sites in South Korea in people aged 3 years or older who received a single dose of QIV during a routine healthcare visit. The most common injection site reaction was pain in injection site infection, with myalgia and malaise being the most typical solicited systemic reactions. Both 8 and 13 participants had reported their injection site and systemic reactions by 8 and 13, respectively; the majority of participants with solicited reactions returned without the need for further intervention; most participants with solicited reactions had no reason to worry about further intervention.

Source link: https://europepmc.org/article/MED/36070176


A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection.

We developed three attenuated replicating stomatitis virus stomatitis virus based vaccine candidates against both SARS-CoV-2 and influenza viruses in this research. Both SARS-CoV-2 SP and influenza M2 protein, as well as high levels of neutralizing antibodies against SARS-CoV-2 Delta and other variant SP-pseudovirus infections have been demonstrated in animal immunization studies, including high amounts of neutralizing antibodies against SARS-CoV-2 Delta and other SARS-CoV-2 B2 proteins. Overall, this report provides solid support for the high success of this bivalent vaccine platform, which can be used and/or quickly modified to produce new vaccines against new or reemerging SARS-CoV-2 variants and influenza A virus infections. IMPORTANCE Given that both COVID-19 and influenza are normally spread through respiratory droplets during the same seasons, it is highly recommended to produce a bivalent vaccine that will simultaneously protect against both COVID-19 and influenza.

Source link: https://europepmc.org/article/MED/36069551


Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine in children and adolescents 6 months through 17 years of age in India.

There are no studies on quadrivalent influenza vaccines for immunization of Indian children. A QIV in Indian children aged 6-35 months and 3-17 years old was determined to have a low immunogenicity, safety, and tolerability by this phase 3, registration study. Subjects were given one or two doses of the study vaccine based on their priming status. In Group 1, 87. 9%, 66. 7 percent, 42. 2%, and 61. 9 percent were among the 82 percent, 69. 9%, and 74% subjects in Group 2 and 89. 9%, respectively, in Group 1 and 89. 0%, 78. 8%, 69. 4%, and 74% subjects in Group 2, respectively. The CTRI Registry No. : Clinical Trials Registry - India The QIV had a positive benefit/risk profile in Indian children/adolescents aged 6 months to 17 years old, according to the CTRI, 2018. URL: CTRI/2018/05/014191 Registry Name: Clinical Trials Registry CTRI (2018) Date of Trial Registration : September 29, 2018 The QIV had a positive benefit/risk profile in Indian children/adolescents aged 6 months to 17 years old.

Source link: https://europepmc.org/article/MED/36053721


Text Message Reminders for the Second Dose of Influenza Vaccine for Children: An RCT.

Among children receiving two influenza doses in a single season, the chances of influenza have been reduced by a small amount. This research was conducted to compare the effectiveness of text message reminders with embedded interactive educational data versus traditional care in terms of influenza vaccination delivery and timeliness. Methods This trial took place between 50 pediatric primary care offices in 24 states from 2017 to 2020, mainly from the American Academy of Pediatrics' Pediatric Research in Office Settings practice-based research network. By April 30, and by day 42, two dose receipts had been tested using Mantel Haenszel methods by practice and language. Conclusions Text message reminders were useful in boosting second dose influenza vaccination delivery across the United States, which was time-distributed.

Source link: https://europepmc.org/article/MED/35965283


Understanding drivers of influenza vaccine hesitancy among pregnant women in China: evidence from an extended theory of planned behavior.

Background Pregnant women's flu vaccination uptake was low, despite being praised as a priority. We conducted a cross-sectional questionnaire survey in China from June to July 2021, investigating both research design and methods. Result - This study included 1283 pregnant women. P 0. 001], subjective values [u03b2 indirect = 0. 142, P 0. 001], perceived social control [u03b2 indirect = 0. 070, P = 0. 004], and vaccine hesitancy were all intended as mediators between attitude [u03b2 indirect = 0. 071 0. 001], subjective beliefs [p = 0. 001], perceived emotional control [u03b2 indirect = 0. 068, P Conclusions The subjective norms dimension has a strong connection with influenza vaccine hesitancy.

Source link: https://europepmc.org/article/MED/36017619


Immunoinformatics design of Bivalent Vaccine targeting S1-NTD and HA2 to simultaneously protect against SARS-CoV-2 and Influenza infections

Introduction: SARS-COV-2 and influenza viruses, two of the most challenging viruses for vaccine development, are causing annual epidemics or increase the pandemic risk. Human IFN-u0263 gene by two three linker was studied in this report by an INF-terminal domain containing the Spike_S1_ N-terminal domain from SARS-COV-2 in-frame to hemagglutinin H2 gene from Influenza A virus and Human IFN u0263 gene. The effectiveness of the made vaccine, which was shown by appropriate expression of designed vaccine candidate tested by in silico cloning in pET and codon optimization, could increase vaccine production into Escherichia coli strain k12. Result and discussion: In conclusion, we suggest that this fusion peptide could be a good design tactic toward producing bivalent vaccines against both COVID-19 and Influenza as a promising vaccine candidate without the need to reformulate or vaccination every year.

Source link: https://europepmc.org/article/PPR/PPR537583

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions